Search | Clinical Trials Finder

Conditions: HIV Infection, Hepatitis C
Interventions: nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more

Conditions: Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
Interventions: Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 14 more

Conditions: Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 17
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 13 more

Conditions: Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
Interventions: Ergocalciferol, placebo; Dietary Supplement
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 10 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension, Atherosclerosis
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 50 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Metabolic-dysfunction Associated Steatotic Liver Disease
Interventions: Essential Amino Acids Supplementation intervention, Low sugar diet; Drug · Other
Lead sponsor: Michigan State University; Other
Eligibility: 11 Years to 17 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: Tirzepatide, Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 141
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: PF-07081532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Hepatic Failure, Liver Failure
Interventions: 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose; Drug
Lead sponsor: Cardiox Corporation; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hepatic; Functional Disturbance
Interventions: NKTR-118; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
Interventions: Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan, Philips 3T Ingenia Elition; Device
Lead sponsor: ContextVision AB; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin alfa; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Rialto, California • Tampa, Florida • San Antonio, Texas

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions: LY3849891, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Orange, California • Rialto, California + 8 more

Conditions: Carcinoma, Hepatocellular
Interventions: Brivanib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • Clleveland, Ohio + 1 more

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions: Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies; Behavioral · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 22 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Moderate Hepatic Impairment, Severe Hepatic Impairment, Healthy Volunteers
Interventions: Lorlatinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Tustin, California • Tampa, Florida • Saint Paul, Minnesota

Conditions: Liver Disease
Interventions: RTA 402; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Liver Diseases, Hepatic Insufficiency
Interventions: Baricitinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Dementia, Potentially Inappropriate Medication Use, Mild Cognitive Impairment (MCI)
Interventions: e-ALIGN Patient-Portal Deprescribing; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy, Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
Interventions: dacomitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Anaheim, California • South Miami, Florida

Conditions: Liver Dysfunction
Interventions: SC Methylnaltrexone (MNTX); Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
Interventions: dasotraline; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Atlanta, Georgia + 2 more

Search by objective public record fields.

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

Longitudinal Study of Mitochondrial Hepatopathies

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction

Age-Related Changes in Body Composition

SMART Diets for MASLD

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

Cardiox Liver Function Test Pivotal Trial

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

The Liver Health Study for Patients with NAFLD

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction